Mad In America: Science, Psychiatry And Social Justice

MIA Report - The Whistleblower and Penn - A Final Accounting of Study 352

Informações:

Synopsis

Welcome to MIA Reports, showcasing our independent and original journalism devoted to rethinking psychiatry. We take selected MIA Reports and provide them as audio articles. Click here for the text version of this and all of our MIA reports. The Whistleblower and Penn: A Final Accounting of Study 352 Written by Peter Simons, read by James Moore, first published on Mad in America, December 29, 2019. Although the general story of ghostwriting in trials of psychiatric drugs is now pretty well known, the details of the corruption in specific trials are still emerging into the public record, often a decade or more after the original sin of fraudulent publication. The latest study to finally see the full light of day is GlaxoSmithKline’s study 352. Perhaps the most infamous ghostwritten study is GSK’s study 329, which, in a 2001 report published in the American Journal of Psychiatry, falsely touted paroxetine (Paxil) as an effective treatment for adolescent depression. The company paid over $3 billion in penalties